Question · Q3 2025
Michael Pollard asked about the progress of Therapulse PFA technology for persistent AF, specifically if it's on track for year-end 2025, if this combination will significantly boost PFA penetration in persistent cases, and if 2026 will be the year for persistent AF to gain higher traction.
Answer
Chief Medical Officer Dr. Ken Stein confirmed that de novo persistent AF ablation is already seeing high uptake, driven by the Advantage trial results which showed excellent long-term outcomes and low redo rates. He noted that the Therawave catheter is well-suited for this strategy. For more complex cases like redo procedures, future advancements such as Therapoint, the Theraflex catheter (in clinical trials), and Cortex technology for precision mapping will be crucial. Dr. Stein reiterated expectations for continued high uptake of Therawave in the de novo persistent population.